Citations

Clear

6273 citation(s) found for "To, Andrew".

Immune-Mediated Autonomic Neuropathies following Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia
Mangaonkar, Abhishek A. , Khateeb, Hassan Al, Duma, Narjust , Louis, Erik K. St. , Patnaik, Mrinal M. , Litzow, Mark R. , Kourelis, Taxiarchis , Mangaonkar, Abhishek A. , St Louis, Erik K, Hogan, William, St Louis, E K , McKeon, Andrew , Hogan, William J.

Mayo Clinic

Case Reports in Hematology | August 27, 2017 | Volume: 2017 | Issue: No issue available | Pages: 1-4

10.1155/2017/6803804 | PMID 28928996 Get It

Background/Aims. Autonomic dysfunction (AD) after allogeneic stem cell transplant (SCT) is a rare occurrence and likely immune-mediated in etiology. There is limited literature on this topic and hence, we wish to briefly describe management of two cases at our institution and their outcomes. Methods. We retrospectively identified two patients with immune-mediated AD after SCT from our database. Immune-mediated AD was defined as AD secondary to an immune-mediated etiology without an alternative cause and responding to immunosuppression. Results. The first case is of a 32-year-old man with acute myeloid leukemia (AML) who underwent double umbilical cord allogeneic SCT. The second patient was a 51-year-old woman with secondary AML who underwent matched-related donor allogeneic SCT. Both underwent an extensive work-up for an underlying etiology prior to treatment with intravenous immunoglobulin (IVIG). Conclusions. AD after SCT is a rare yet significant clinical entity. A work-up of underlying etiology should be performed. IVIG is a treatment option for these patients.
Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells
Ruvolo, Peter P. , Ligresti, Giovanni , Ratti, Stefano , Tafuri, Agostino , Steelman, Linda S., Candido, Saverio , Abrams, Stephen Lee , Ruvolo, Vivian R. , Martelli, Alberto Maria , Cocco, Lucio , Libra, Massimo , McCubrey, James Andrew , Ratti, Stefano

Mayo Clinic

Oncotarget | August 24, 2017 | Volume: 8 | Issue: 44 | Pages: 76525-76557

10.18632/oncotarget.20408 | PMID 29100331 Get It

BRAF V600E Mutations Occur in a Subset of Glomus Tumors, and Are Associated With Malignant Histologic Characteristics
Dashti, Nooshin K. , Bahrami, Armita , Lee, Seung Joon , Jenkins, Sarah M. , Folpe, Andrew L. , Boland, Jennifer M. , Karamzadeh Dashti, Nooshin, Rodríguez, Fausto J.

Mayo Clinic

American Journal of Surgical Pathology | August 22, 2017 | Volume: 41 | Issue: 11 | Pages: 1532-1541

10.1097/pas.0000000000000913 | PMID 28834810 Get It

Glomus tumors are rare mesenchymal neoplasms with a phenotype akin to the modified smooth muscle cells of the glomus body. Most are benign, but rare examples show malignant histologic characteristics and aggressive behavior. We recently encountered a malignant glomus tumor with BRAF V600E mutation. We sought to study a large cohort for this mutation, with particular attention to associated malignant histologic characteristics. Tumors were classified based on WHO criteria as benign, uncertain malignant potential (glomus tumors of uncertain malignant potential—GT-UMP), or malignant. Tumors were screened for BRAF V600E by immunohistochemistry, and positive staining was evaluated further by Sanger sequencing. A total of 102 glomus tumors were included and classified as benign (57, 56%), GT-UMP (15, 15%) and malignant (30, 29%). Tumors occurred in patients aged 8 to 89.9 years (median: 50.2), without sex predilection (55% men). Most occurred in the superficial soft tissue (84%) and upper extremities (55%). Six of 95 tested cases had BRAF V600E mutation (6%), including 0 of 57 benign tumors, 3 of 14 GT-UMP (21%), and 3 of 24 malignant tumors (12%). Follow-up was obtained for 59 cases (median: 75.7 mo, range: 7.8 to 268.5). Three of 11 malignant tumors (27%) had progressive disease: 1 with metastasis to brain and heart, 1 with enlarging residual disease, and 1 with recurrence. Two of 4 GT-UMP (50%) had progressive disease: 1 with metastasis to lung, and 1 with local recurrence (50%). Three of 44 benign tumors (7%) had local recurrence. Two of 5 patients with BRAF V600E had progression, including 1 GT-UMP with local recurrence and 1 malignant tumor with enlarging residual disease. In summary, BRAF V600E mutation was detected in 6% of glomus tumors, all of which were malignant or GT-UMP. This mutation may be associated with a malignant phenotype, although study of additional cases is needed. In patients with progressive disease, BRAF could be a promising therapeutic target.
Persistent acute kidney injury following transcatheter aortic valve replacement
Thongprayoon, Charat , Cheungpasitporn, Wisit , Srivali, Narat , Kittanamongkolchai, Wonngarm , Harrison, Andrew M. , Greason, Kevin L. , Mao, Michael A. , Harrison, Andrew Marc , Cheungpasitporn, Wisit , Thongprayoon, Charat , Srivali, Narat , Kashani, Kianoush

Mayo Clinic

Journal of Cardiac Surgery | August 22, 2017 | Volume: 32 | Issue: 9 | Pages: 550-555

10.1111/jocs.13200 | PMID 28833503 Get It

A Tupaia paramyxovirus vector system for targeting and transgene expression
Engeland, Christine E. , Bossow, Sascha, Hudacek, Andrew W., Hoyler, Birgit, Förster, Judith M., Veinalde, Rūta , Jäger, Dirk, Cattaneo, Roberto , Ungerechts, Guy , Springfeld, Christoph

Mayo Clinic

Journal of General Virology | August 15, 2017 | Volume: 98 | Issue: 9 | Pages: 2248-2257

10.1099/jgv.0.000887 | PMID 28809150 Get It

S100A4 Is a Biomarker and Regulator of Glioma Stem Cells That Is Critical for Mesenchymal Transition in Glioblastoma
Chow, Kin-Hoe, Park, Hee Jung , Yamamoto, Keiko , Gallup, Andrew D., Chen, Yuanxin , Jiang, Wen , Steindler, Dennis A. , Neilson, Eric G. , Kim, Betty Y.S. , Yun, Kyuson , Jiang, Wen , Kim, Betty Y S , George, Joshy , Graber, Joel H.

Mayo Clinic

Cancer Research | August 14, 2017 | Volume: 77 | Issue: 19 | Pages: 5360-5373

10.1158/0008-5472.can-17-1294 | PMID 28807938 Get It

Abstract Glioma stem cells (GSC) and epithelial–mesenchymal transition (EMT) are strongly associated with therapy resistance and tumor recurrence, but the underlying mechanisms are incompletely understood. Here, we show that S100A4 is a novel biomarker of GSCs. S100A4+ cells in gliomas are enriched with cancer cells that have tumor-initiating and sphere-forming abilities, with the majority located in perivascular niches where GSCs are found. Selective ablation of S100A4-expressing cells was sufficient to block tumor growth in vitro and in vivo. We also identified S100A4 as a critical regulator of GSC self-renewal in mouse and patient-derived glioma tumorspheres. In contrast with previous reports of S100A4 as a reporter of EMT, we discovered that S100A4 is an upstream regulator of the master EMT regulators SNAIL2 and ZEB along with other mesenchymal transition regulators in glioblastoma. Overall, our results establish S100A4 as a central node in a molecular network that controls stemness and EMT in glioblastoma, suggesting S100A4 as a candidate therapeutic target. Cancer Res; 77(19); 5360–73. ©2017 AACR.
A quantitative, multi-national and multi-stakeholder assessment of barriers to the adoption of cell therapies
Davies, Benjamin M. , Rikabi, Sarah , Wartolowska, Karolina , French, Anna , MacLaren, Robert E. , Williams, David , Bure, Kim, Pinedo‐Villanueva, Rafael , Mathur, Anthony , Birchall, Martin , Snyder, Evan , Reeve, Brock , Morrey, Mark, Smith, James Andrew Buchan , Morrey, Mark E. , Atala, Anthony , Brindley, David A.

Mayo Clinic

Journal of Tissue Engineering | August 11, 2017 | Volume: 8 | Issue: No issue available | Pages: No page available

10.1177/2041731417724413 | PMID 28835816 Get It

Cellular therapies, such as stem cell–based treatments, have been widely researched and numerous products and treatments have been developed. Despite this, there has been relatively limited use of these technologies in the healthcare sector. This study sought to investigate the perceived barriers to this more widespread adoption. An anonymous online questionnaire was developed, based on the findings of a pilot study. This was distributed to an audience of clinicians, researchers and commercial experts in 13 countries. The results were analysed for all respondents, and also sub-grouped by geographical region, and by profession of respondents. The results of the study showed that the most significant barrier was manufacturing, with other factors such as efficacy, regulation and cost-effectiveness being identified by the different groups. This study further demonstrates the need for these important issues to be addressed during the development of cellular therapies to enable more widespread adoption of these treatments.
Quantifying the Effects of Prior Acetyl-Salicylic Acid on Sepsis-Related Deaths: An Individual Patient Data Meta-Analysis Using Propensity Matching*
Trauer, James M. , Muhi, Stephen , McBryde, Emma S. , Harbi, Shmeylan Al, Arabi, Yaseen M. , Boyle, Andrew , Cartin‐Ceba, Rodrigo , Chen, Yung‐Tai , Gajić, Ognjen, Godsell, Jack , Gong, Michelle N. , Kor, Daryl J. , Lösche, Wolfgang, McAuley, Daniel F. , O’Neal, Hollis R. , Otto, Gordon P , Soßdorf, Maik, Tsai, Min-Juei, Valerio-Rojas, Juan Carlos , Poll, Tom van der , Ware, Lorraine B. , Widmer, Andreas F. , Wiewel, Maryse A. , Winning, Johannes, Eisen, Damon P. , Trauer, James, Harbi, Shmeylan A. Al , Chen, Wei, Falcone, Marco , Gajic, Ognjen , Osthoff, Michael Friedrich , Violi, Francesco , Arabi, Yaseen M

Mayo Clinic

Critical Care Medicine | August 10, 2017 | Volume: 45 | Issue: 11 | Pages: 1871-1879

10.1097/ccm.0000000000002654 | PMID 28799949 Get It

Objective: The primary objective was to conduct a meta-analysis on published observational cohort data describing the association between acetyl-salicylic acid (aspirin) use prior to the onset of sepsis and mortality in hospitalized patients. Study Selection: Studies that reported mortality in patients on aspirin with sepsis with a comparison group of patients with sepsis not on prior aspirin therapy were included. Data Sources: Fifteen studies described hospital-based cohorts (n = 17,065), whereas one was a large insurance-based database (n = 683,421). Individual-level patient data were incorporated from all selected studies. Data Extraction: Propensity analyses with 1:1 propensity score matching at the study level were performed, using the most consistently available covariates judged to be associated with aspirin. Meta-analyses were performed to estimate the pooled average treatment effect of aspirin on sepsis-related mortality. Data Synthesis: Use of aspirin was associated with a 7% (95% CI, 2–12%; p = 0.005) reduction in the risk of death as shown by meta-analysis with considerable statistical heterogeneity (I 2 = 61.6%). Conclusions: These results are consistent with effects ranging from a 2% to 12% reduction in mortality risk in patients taking aspirin prior to sepsis onset. This association anticipates results of definitive studies of the use of low-dose aspirin as a strategy for reduction of deaths in patients with sepsis.
Structural and Functional Changes in Human Kidneys with Healthy Aging
Hommos, Musab S. , Glassock, Richard J. , Hommos, Musab S , Rule, Andrew D.

Mayo Clinic

Journal of the American Society of Nephrology | August 8, 2017 | Volume: 28 | Issue: 10 | Pages: 2838-2844

10.1681/asn.2017040421 | PMID 28790143 Get It

Aging is associated with significant changes in structure and function of the kidney, even in the absence of age-related comorbidities. On the macrostructural level, kidney cortical volume decreases, surface roughness increases, and the number and size of simple renal cysts increase with age. On the microstructural level, the histologic signs of nephrosclerosis (arteriosclerosis/arteriolosclerosis, global glomerulosclerosis, interstitial fibrosis, and tubular atrophy) all increase with age. The decline of nephron number is accompanied by a comparable reduction in measured whole-kidney GFR. However, single-nephron GFR remains relatively constant with healthy aging as does glomerular volume. Only when glomerulosclerosis and arteriosclerosis exceed that expected for age is there an increase in single-nephron GFR. In the absence of albuminuria, age-related reduction in GFR with the corresponding increase in CKD (defined by an eGFR<60 ml/min per 1.73 m 2 ) has been shown to associate with a very modest to no increase in age-standardized mortality risk or ESRD. These findings raise the question of whether disease labeling of an age-related decline in GFR is appropriate. These findings also emphasize the need for a different management approach for many elderly individuals considered to have CKD by current criteria.
Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis
Alberts, Rudi , Vries, Elisabeth M. G. de, Goode, Elizabeth C. , Jiang, Xiaojun , Sampaziotis, Fotis , Rombouts, Krista , Böttcher, Katrin , Folseraas, Trine , Weismüller, Tobias J. , Alexander, Graeme, Alvaro, Domenico , Bergquist, Annika , Björkström, Niklas K. , Beuers, Ulrich , Boberg, Kirsten Muri , Bowlus, Christopher L. , Bragazzi, Maria Consiglia , Chazouillères, Olivier , Cheung, Angela , Dalekos, Georgios, Eaton, John E. , Eksteen, Bertus , Ellinghaus, David , Färkkilâ, Martti , Festen, Eleonora A. , Floreani, Annarosa , Franceschet, I., Gotthardt, Daniel , Hoek, Bart van , Holm, Kristian , Hov, Johannes R. , Imhann, Floris , Juran, Brian D., Lenzen, Henrike , Marschall, Hanns–Ulrich , Marzioni, Marco , Melum, Espen , Milkiewicz, Piotr , Müller, Tobias , Parés, Albert , Rupp, Christian , Rust, Christian, Sandford, Richard , Schrumpf, Erik, Silverberg, Mark S. , Srivastava, Brijesh, Sterneck, Martina , Teufel, Andreas , Vallier, Ludovic , Verheij, Joanne , Vila, Arnau Vich , Vries, Boudewijn de, Zachou, Kalliopi , Chapman, Roger W. , Manns, Michael P. , Rushbrook, Simon, Anderson, Carl A. , Karlsen, Tom H. , Ponsioen, Cyriel Y. , Weersma, Rinse K. , Eaton, John, Lazaridis, Konstantinos N. , Ellinghaus, David , Bowlus, Christopher L , Marzioni, Marco , Mason, Andrew L. , Wang, Weiwei , Bjornsson, Einar Stefan , Carbone, Marco , Dalekos, Georgios, Hirschfield, Gideon M. , Hohenester, Simon D. , Invernizzi, Pietro , Lieb, Wolfgang , Liu, Jimmy Z. , Schramm, Christoph , Schreiber, Stefan , Pinzani, Massimo , Franke, André , Bergquist, Annika , Milkiewicz, Piotr , Alvaro, Domenico , Hov, Johannes R , Anderson, Carl A

Mayo Clinic

Gut | August 4, 2017 | Volume: 67 | Issue: 8 | Pages: 1517-1524

10.1136/gutjnl-2016-313598 | PMID 28779025 Get It

Objective Primary sclerosing cholangitis (PSC) is a genetically complex, inflammatory bile duct disease of largely unknown aetiology often leading to liver transplantation or death. Little is known about the genetic contribution to the severity and progression of PSC. The aim of this study is to identify genetic variants associated with PSC disease progression and development of complications. Design We collected standardised PSC subphenotypes in a large cohort of 3402 patients with PSC. After quality control, we combined 130 422 single nucleotide polymorphisms of all patients—obtained using the Illumina immunochip—with their disease subphenotypes. Using logistic regression and Cox proportional hazards models, we identified genetic variants associated with binary and time-to-event PSC subphenotypes. Results We identified genetic variant rs853974 to be associated with liver transplant-free survival (p=6.07×10–9). Kaplan-Meier survival analysis showed a 50.9% (95% CI 41.5% to 59.5%) transplant-free survival for homozygous AA allele carriers of rs853974 compared with 72.8% (95% CI 69.6% to 75.7%) for GG carriers at 10 years after PSC diagnosis. For the candidate gene in the region, RSPO3, we demonstrated expression in key liver-resident effector cells, such as human and murine cholangiocytes and human hepatic stellate cells. Conclusion We present a large international PSC cohort, and report genetic loci associated with PSC disease progression. For liver transplant-free survival, we identified a genome-wide significant signal and demonstrated expression of the candidate gene RSPO3 in key liver-resident effector cells. This warrants further assessments of the role of this potential key PSC modifier gene.